Laekna, Inc. (HKG:2105)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.67
-0.74 (-5.96%)
Last updated: May 28, 2026, 10:48 AM HKT
Market Cap5.22B -3.0%
Revenue (ttm)118.76M
Net Income-255.19M
EPS-0.66
Shares Out 420.55M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume965,500
Open12.41
Previous Close12.41
Day's Range11.63 - 12.41
52-Week Range10.30 - 23.50
Beta-1.04
AnalystsStrong Buy
Price Target24.89 (+113.28%)
Earnings DateMay 27, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative brea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 83
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2105
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements